Phaseline

Companies › Hinova Pharmaceuticals

Hinova Pharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 1 Phase 1, 1 Phase 2, 1 Phase 3; Oncology, Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HC-1119–Phase 3MCRPC–
HP515–Phase 2NAFLD (Non-alcoholic Fatty Liver Disease)Dec 2026
HP518–Phase 1Metastatic Castration-resistant Prostate Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03851640HC-1119Phase 3MCRPCOncologySep 2025
NCT06155084HP518Phase 1Metastatic Castration-resistant Prostate CancerOncologyMar 2026
NCT07308548HP515Phase 2NAFLD (Non-alcoholic Fatty Liver Disease)GastroenterologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Xuanzhu Biopharmaceutical Institut de Recherches Internationales Servier (I.R.I.S.) Blue Earth Diagnostics Shenzhen TargetRx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.